Result of AGM

Dr. Martens PLC
13 July 2023
 

13 July 2023

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

13 JULY 2023

The Company announces the results of voting at its Annual General Meeting held earlier today and confirms that all resolutions were duly passed on a poll with majorities as set out below.

Resolutions 1 to 16 and 20 were proposed as Ordinary Resolutions and resolutions 17 to 19 and 21 as Special Resolutions.

Resolution

 

 

 

Votes
For

 

 

%

 

 

Votes Against

 

 

%

 

 

Votes
Total

 

 

Votes Withheld

 

% Voting

Capital Instructed

01

Receive the 2023 Annual Report and Accounts

791,907,515

100.00

15,601

0.00

791,923,116

33,511,941

79.11%

02

Approve the Directors' Remuneration Report

789,249,709

99.70

2,387,991

0.30

791,637,700

33,798,706

79.08%

03

Approve the Final Dividend

792,678,036

100.00

8,616

0.00

792,686,652

32,749,754

79.19%

04

Elect Andrew Harrison

791,490,859

99.98

174,650

0.02

791,665,509

33,770,897

79.09%

05

Re-elect Paul Mason

770,008,610

98.35

12,906,128

1.65

782,914,738

42,521,668

78.21%

06

Re-elect Kenny Wilson

786,317,927

99.20

6,370,872

0.80

792,688,799

32,747,607

79.19%

07

Re-elect Jon Mortimore

788,658,067

99.49

4,029,383

0.51

792,687,450

32,748,956

79.19%

08

Re-elect Ian Rogers

785,437,812

99.21

6,227,697

0.79

791,665,509

33,770,897

79.09%

09

Re-elect Ije Nwokorie

788,930,301

99.66

2,727,826

0.34

791,658,127

33,778,279

79.09%

10

Re-elect Lynne Weedall

775,629,826

98.86

8,906,789

1.14

784,536,615

40,899,791

78.37%

11

Re-elect Robyn Perriss

778,626,724

98.35

13,035,285

1.65

791,662,009

33,774,397

79.09%

12

Re-elect Tara Alhadeff

787,976,513

99.41

4,705,937

0.59

792,682,450

32,753,956

79.19%

13

Re-appoint PricewaterhouseCoopers LLP as auditor

791,210,597

99.94

458,111

0.06

791,668,708

33,767,698

79.09%

14

Authorise the Audit & Risk Committee to determine the Auditor's remuneration

792,677,114

100.00

9,211

0.00

792,686,325

32,750,081

79.19%

15

Authorise the Company and its subsidiaries to make political donations

788,454,942

99.47

4,233,372

0.53

792,688,314

32,748,092

79.19%

16

Authorise allotment of shares

778,667,872

98.23

14,009,348

1.77

792,677,220

32,759,186

79.19%

 17

Authorise general disapplication of pre-emption rights*

774,627,295

97.72

18,056,599

2.28

792,683,894

32,752,512

79.19%

18

Authorise additional disapplication of pre-emption rights*

765,565,585

96.58

27,109,427

3.42

792,675,012

32,761,394

79.19%

19

Authorise purchase of own shares*

792,179,815

99.94

473,625

0.06

792,653,440

32,782,966

79.19%

20

Approve waiver of Rule 9 Offer obligation

(see note 1)

383,340,147

91.84

34,052,637

8.16

417,392,784

38,101,183

41.70%

21

Authorise calling of general meetings on 14 days' notice*

781,330,267

98.57

11,358,493

1.43

792,688,760

32,747,646

79.19%

*Special Resolution

 

The votes of independent shareholders on the resolutions concerning the election or re-election of the Independent Non-Executive Directors are set out below:

Resolution

 

 

Votes
For

 

%

 

Votes Against

 

%

 

Votes
Total

 

Votes Withheld

 

% Independent

Capital Instructed

04

Elect Andrew Harrison

421,548,419

99.96

174,650

0.04

421,723,069

33,770,897

66.83%

08

Re-elect Ian Rogers

415,495,372

98.52

6,227,697

1.48

421,723,069

33,770,897

66.83%

09

Re-elect Ije Nwokorie

418,987,861

99.35

2,727,826

0.65

421,715,687

33,778,279

66.83%

10

Re-elect Lynne Weedall

405,687,386

97.85

8,906,789

2.15

414,594,175

40,899,791

65.70%

11

Re-elect Robyn Perriss

408,684,284

96.91

13,035,285

3.09

421,719,569

33,774,397

66.83%

 

Notes:

  1. IngreLux S.àr.l was considered to be interested in the outcome of Resolution 20 and, consequently, did not vote on that Resolution in accordance with the provisions of the City Code on Takeovers and Mergers. As a result, 631,064,067 of the ordinary shares in issue were eligible to vote on this Resolution, these shares not being held by IngreLux S.àr.l.
  2. Votes "For" and "Against" are expressed as a percentage of votes received.
  3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
  4. As at 6.30pm on 11 July 2023 the Company had a total of 1,001,006,507 ordinary shares with voting rights in issue. The total independent voting capital, used to calculate the votes of independent shareholders on resolutions 4, 8 to 11 and 20, was 631,064,067.
  5. In accordance with Listing Rule 9.6.2R, copies of the resolutions passed as special business will shortly be available for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.  

 

Enquiries

Company Secretariat

Paul Rolling, Assistant Company Secretary                         +44 7584 243562


Investors and analysts                         

Bethany Barnes, Director of Investor Relations                    +44 7825 187465

                                                            bethany.barnes@drmartens.com

Media                                                     

Gill Hammond, Director of Communications                          +44 7384 214248

Maitland                                                                                     +44 20 7379 5151

Clinton Manning                                                                        +44 7711 972 662

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, “Docs” or “DM’s” are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Dr. Martens (DOCS)
UK 100

Latest directors dealings